XML 25 R8.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2025
Oct. 31, 2024
Oct. 31, 2023
Cash flows from operating activities:      
Net Income $ 1,303.0 $ 1,289.0 $ 1,240.0
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 288.0 257.0 271.0
Share-based compensation 128.0 129.0 111.0
Deferred taxes expense (benefit) (130.0) (64.0) (56.0)
Excess and obsolete inventory related charges 45.0 45.0 40.0
Net gain (loss) on equity securities (36.0) 6.0 (41.0)
Asset impairment charges 15.0 19.0 277.0
Change in fair value of contingent consideration 0.0 0.0 1.0
Net gain on Divestiture of Business 0.0 0.0 43.0
Other non-cash expense, net 5.0 (1.0) 6.0
Changes in assets and liabilities:      
Accounts receivable, net (149.0) 7.0 132.0
Inventory (97.0) 34.0 (33.0)
Accounts payable 16.0 103.0 (171.0)
Employee compensation and benefits 69.0 (12.0) (91.0)
Other assets and liabilities 30.0 (49.0) 47.0
Net cash provided by operating activities 1,559.0 1,751.0 1,772.0
Cash flows from investing activities:      
Payments to acquire property, plant and equipment (407.0) (378.0) (298.0)
Proceeds from the sale of equity securities 8.0 0.0 5.0
Payments to acquire equity securities 0.0 (5.0) (8.0)
Proceeds from convertible note 2.0 0.0 4.0
Payment in exchange for convertible note (1.0) (13.0) (12.0)
Proceeds from Divestiture of Businesses 0.0 0.0 50.0
Acquisitions of businesses and intangible assets, net of cash acquired 4.0 (862.0) (51.0)
Net cash used in investing activities (394.0) (1,258.0) (310.0)
Cash flows from financing activities:      
Proceeds from the issuance of common stock under employee stock plans 72.0 77.0 67.0
Payment of taxes related to net share settlement of equity awards (29.0) (30.0) (54.0)
Payments for repurchase of common stock (425.0) (1,150.0) (575.0)
Payment of excise taxes related to repurchases of common stock (10.0) (3.0) 0.0
Payment of dividends (282.0) (274.0) (265.0)
Proceeds from Issuance of Long-Term Debt 4.0 1,197.0 0.0
Repayments of Long-Term Debt (3.0) (600.0) 0.0
Payments of debt issuance costs 0.0 (9.0) 0.0
Net proceeds from (Repayments of ) Short-Term Debt (42.0) 40.0 (35.0)
Payment for Contingent Consideration 0.0 0.0 (68.0)
Net cash used in financing activities (715.0) (752.0) (930.0)
Effect of exchange rate movements 9.0 (2.0) 5.0
Net increase (decrease) in cash, cash equivalents and restricted cash 459.0 (261.0) 537.0
Cash, cash equivalents and restricted cash at beginning of year 1,332.0 1,593.0 1,056.0
Cash, cash equivalents and restricted cash at end of year 1,791.0 1,332.0 1,593.0
Supplemental Cash Flow Information [Abstract]      
Income Taxes Payments, Net of refunds received 318.0 314.0 199.0
Interest payments, net of capitalized interest 101.0 80.0 89.0
Net change in property, plant and equipment included in accounts payable and accrued liabilities-increase (decrease) 11.0 9.0 4.0
Share Repurchase Program, Excise Tax, Payable $ 3.0 $ 10.0 3.0
Resolution Bioscience, Inc.      
Adjustments to reconcile net income to net cash provided by operating activities:      
Net gain on Divestiture of Business     43.0
Cash flows from investing activities:      
Proceeds from Divestiture of Businesses     $ 50.0